Hyperliquid Strategies(NASDAQ) PURR

Hyperliquid Strategies manages a treasury of digital assets. It focuses on the Hyperliquid blockchain ecosystem. The firm also runs a biotech business.

Inside the Product Lineup

• Digital Treasury: Manages a portfolio of HYPE tokens, which are the native assets used on the Hyperliquid blockchain network.
• Staking Rewards: Earns income by locking tokens to support the security and operations of a blockchain; generated 100% of revenue in the quarter ended December 31, 2025.
• Biotech Research: Conducts medical studies through the Sonnet subsidiary; focuses on developing treatments for cancer and other diseases.

Strategic Moves and Funding

• Completed a reverse recapitalization with Rorschach I LLC on December 2, 2025.
• Acquired Sonnet BioTherapeutics Holdings, Inc. on December 2, 2025, which now operates as a wholly owned subsidiary.
• Established a $1 billion equity facility with Chardan Capital Markets LLC to fund future operations and asset purchases.
• Authorized a stock repurchase program in December 2025 to buy back up to $30 million of outstanding common stock.

Operational Strengths

The company provides institutional investors with a regulated way to access the Hyperliquid blockchain ecosystem. It uses technical experts from Rorschach Advisors LLC to optimize its digital asset management and treasury strategy.

The Latest Financial Data

• Staking revenue was $500,000 for the quarter ended December 31, 2025.
• Net loss reached $304.5 million for the quarter ended December 31, 2025, due to non-cash losses on digital asset commitments.
• Cash and equivalents totaled $281.9 million as of December 31, 2025.
• Treasury holdings included 12.9 million HYPE tokens valued at $327.6 million on December 31, 2025.

Bottom Line

Hyperliquid Strategies has evolved into a public digital asset treasury while maintaining a secondary focus on biotechnology. Its growth is driven by the accumulation of blockchain assets and active engagement in decentralized finance.